Leadership
2025 is likely to be a game-changing year for the pharmaceutical industry. Generics Bulletin sat down with Medicines for Europe’s Adrian van den Hoven and Beata Stepniewska to discuss the opportunities of the Critical Medicines Act and EU pharmaceutical legislation revision.
In a wide-ranging conversation, the AAM’s president and CEO John Murphy talks to Generics Bulletin about how the US industry association is planning to gain traction with the new Trump administration by adopting “a much more aggressive communications approach” on topics including medicines shortages, trade tariffs, PBM reform, the IRA and biosimilar interchangeability.
A new US presidential administration brings both challenges and opportunities for the off-patent industry. Speaking to Generics Bulletin on the sidelines of the AAM’s annual conference earlier this month, the association’s chair and Sandoz North America president Keren Haruvi discusses how the group plans to make its voice heard on key priorities including tariffs, PBM reform, and regulatory streamlining.
Cosette Pharmaceuticals has made two key executive appointments as it looks to build up its business. Meanwhile, Canada’s CGPA has named a chair and vice-chair, and Chanelle and Neuraxpharm have announced their own executive changes.
Adial Pharmaceuticals’ CEO Cary Claiborne discussed with Generics Bulletin how repurposing antinausea drug ondansetron and genetically targeting patients with specific biomarkers can address the unmet need in the current treatment of addiction.
After more than three decades with Sandoz and its former president Novartis, Francisco Ballester is retiring, with his former International region president role going to Sandoz’s global biosimilars head, Peter Stenico.
The Teva v. Amneal battle over inhaler patents in the FDA’s Orange Book has become a noteworthy case that will impact both branded and generic drug companies. Yet, the clarity over patent listings might be overshadowed by possible future litigations, discussed law firm Polsinelli’s chair Chad Landmon with Generics Bulletin.
Almost a year since the establishment of an expanded CDMO business unit, Canada’s Pharmascience has doubled down on its plans to expand its presence through the pharmaceutical industry.
As Sandoz’s north American president Keren Haruvi gears up for a second term as chair of US generics and biosimilars association the AAM, other firms – including Sunshine Biopharma, Centrient and Rosemont – have also announced executive appointments.
Recently-appointed president of Medicines for Europe Stephan Eder speaks to Generics Bulletin about the off-patent association’s priorities to secure a sustainable operating environment for the generics, biosimilars and value-added medicines sector in Europe.
In an exclusive interview with Generics Bulletin, Aspargo Labs CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.
Rounding up another important year in the fight against HIV, the MPP’s executive director Charles Gore speaks to Generics Bulletin about the organization’s biggest milestones in the past 12 months.
Medicines for Europe names a new president, the IGBA reveals its latest chair, and Chanelle and Xbrane announce fresh faces in key roles, in our latest round-up of off-patent industry appointments.
Insud Pharma chief executive Lucas Sigman has moved up to lead the IGBA’s CEO Advisory Committee, replacing Lupin chief Vinita Gupta at the helm. Meanwhile, Apotex president and CEO Allan Oberman has become vice-chair.
In the final instalment of his three-part interview with Generics Bulletin, Sandoz CEO Richard Saynor talks about opportunities on the horizon, including GLP-1s, ADCs and oligonucleotides – and explains why he has no interest in pursuing value added medicines.
In the second part of our exclusive interview with Richard Saynor, the Sandoz CEO discusses the importance of both the small-molecule generics and biosimilars businesses for the company, talking about portfolio selection and specific product opportunities for biosimilars while also contrasting the firm’s European and US generics leadership aspirations and approaches to the business.
In the first instalment of a three-part interview with Richard Saynor, the Sandoz CEO talks about the aftermath of the company’s spinoff from former parent Novartis and the work still left to do; the increasing prominence of biosimilars for Sandoz; the firm’s investments in manufacturing; thoughts on the potential for significant M&A; and future opportunities for the industry leader.
EuroAPI says it is moving “into a new chapter” after appointing another new CEO, marking the latest change in leadership after what has been a turbulent year for the European active pharmaceutical ingredients specialist.
Following its recent presentation of results for the third quarter of the 2024 fiscal year, Organon’s US biosimilars lead Jon Martin spoke to Generics Bulletin about the company’s adalimumab plans and strategy with upcoming launches, as well as how these will benefit from the firm’s focus on women’s health.
Europe risks “missing out on a massive opportunity” if it does not improve its efforts to recognize and take advantage of the benefits of value added medicines, according to Medicines for Europe sector chair and Pharmanovia CEO James Burt.